Pseudoprogression in advanced non-small cell lung cancer treated with combination chemoimmunotherapy: a case report by Amrit S. Gonugunta, Mitchell S. von Itzstein, David E. Gerber

Get full text

How lung cancer cells change identity by Mitchell S von Itzstein, Benjamin J Drapkin, John D Minna

Get full text

Acknowledging and addressing real-world challenges to treating immune-related adverse events by Bonnie L Bermas, Mitchell S von Itzstein, David E Gerber, Alexa Meara

Get full text

Closing the gap: Contribution of surgical best practices to outcome differences between high‐ and low‐volume centers for lung cancer resection by Mitchell S. vonItzstein, Rong Lu, Kemp H. Kernstine, Ethan A. Halm, Shidan Wang, Yang Xie, David E. Gerber

Get full text

Distinct NSCLC EGFR Variants in a Family With Li-Fraumeni Syndrome: Case Report by Shelby Edmondson, BA, Mitchell S. von Itzstein, MD, Brian Reys, MS, Melissa Mayer, BA, Jeffrey Gagan, MD, David E. Gerber, MD

Get full text

Distinct autoantibody profiles across checkpoint inhibitor types and toxicities by Hong Mu-Mosley, Mitchell S. von Itzstein, Farjana Fattah, Jialiang Liu, Chengsong Zhu, Yang Xie, Edward K. Wakeland, Jason Y. Park, Brad S. Kahl, Catherine S. Diefenbach, David E. Gerber

Get full text

Use of artificial intelligence chatbots in clinical management of immune-related adverse events by Jarushka Naidoo, Igor Puzanov, Paolo A Ascierto, Marc S Ernstoff, Douglas B Johnson, Fei Ye, Mitchell S von Itzstein, David E Gerber, Benjamin Switzer, Aliyah Pabani, Hannah Burnette, Run Fan

Get full text

T-cell tolerant fraction as a predictor of immune-related adverse events by Yang Xie, Shaheen Khan, Prithvi Raj, Edward K Wakeland, Mitchell S von Itzstein, Farjana Fattah, Jason Y Park, David Hsiehchen, Jared Ostmeyer, David E Gerber, Mary Gwin, Rodrigo Catalan

Get full text

Highly variable timing renders immunotherapy efficacy and toxicity impractical biomarkers of one another in clinical practice by Mitchell S. von Itzstein, Mitchell S. von Itzstein, Yuqiu Yang, Yiqing Wang, David Hsiehchen, Thomas Y. Sheffield, Farjana Fattah, Vinita Popat, Murtaza Ahmed, Jade Homsi, Jade Homsi, Jonathan E. Dowell, Jonathan E. Dowell, Sawsan Rashdan, Sawsan Rashdan, Jay Lohrey, Jay Lohrey, Hans J. Hammers, Hans J. Hammers, Randall S. Hughes, Randall S. Hughes, Tao Wang, Tao Wang, Yang Xie, Yang Xie, David E. Gerber, David E. Gerber, David E. Gerber

Get full text

Systemic immune parameters after prior radiation therapy in patients receiving immune checkpoint inhibitors by Vatsala Mundra, Yuqiu Yang, Mitchell S. von Itzstein, Farjana Fattah, Amrit S. Gonugunta, Raquibul Hannan, Laurentiu M. Pop, Yuanyuan Zhang, Yiqing Wang, Thomas Sheffield, Yang Xie, Jonathan E. Dowell, Jade Homsi, Sawsan Rashdan, Jason Park, Quan-Zhen Li, Edward K. Wakeland, David E. Gerber

Get full text

Association between body mass index, dosing strategy, and efficacy of immune checkpoint inhibitors by Yang Xie, Vinita Popat, Shaheen Khan, Saad A Khan, Edward K Wakeland, Quan-Zhen Li, Murtaza Ahmed, Mitchell S von Itzstein, Thomas Sheffield, Farjana Fattah, Jason Y Park, Jessica M Saltarski, Yvonne Gloria-McCutchen, David Hsiehchen, Jared Ostmeyer, Nazima Sultana, David E Gerber

Get full text

Racial Differences in Systemic Immune Parameters in Individuals With Lung Cancer by Mitchell S. von Itzstein, MD, Jialiang Liu, PhD, Hong Mu-Mosley, PhD, Farjana Fattah, PhD, Jason Y. Park, MD, PhD, Jeffrey A. SoRelle, MD, J. David Farrar, PhD, Mary E. Gwin, MD, David Hsiehchen, MD, Yvonne Gloria-McCutchen, Edward K. Wakeland, PhD, Suzanne Cole, MD, Sheena Bhalla, MD, Radhika Kainthla, MD, Igor Puzanov, MD, MSCI, Benjamin Switzer, DO, MHSA, MS, Gregory A. Daniels, MD, PhD, Yousef Zakharia, MD, Montaser Shaheen, MD, Jianjun Zhang, MD, PhD, Yang Xie, PhD, David E. Gerber, MD

Get full text